Synergistic effect of acetylcholinesterase inhibition (donepezil) and 5-HT 4 receptor activation (RS67333) on object recognition in mice

Behavioural Brain Research

Volumn 230, Issue 1, 2012, Pages 304-308

  Freret, Thomas ^a   Bouet, Valentine ^a   Quiedeville, Anne ^a   Nee, Gérald ^a   Dallemagne, Patrick ^b   Rochais, Christophe ^b   Boulouard, Michel ^a  

^a UNIVERSITÉ DE CAEN   (France)

^b CENTRE D ETUDES ET DE RECHERCHE SUR LE MÉDICAMENT DE NORMANDIE   (France)

Author keywords

Acetylcholinesterase; Alzheimer disease; Amyloid precursor protein; Memory; MTDL; Serotonin

Indexed keywords

1 (4 AMINO 5 CHLORO 2 METHOXYPHENYL) 3 (1 BUTYL 4 PIPERIDINYL) 1 PROPANONE; 5 FLUORO 2 METHOXY 1H INDOLE 3 CARBOXYLIC ACID 1 [2 (METHYLSULFONAMIDO)ETHYL] 4 PIPERIDINYLMETHYL ESTER; ACETYLCHOLINESTERASE; DONEPEZIL;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CHEMICAL STRUCTURE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; ENZYME INHIBITION; MALE; MEMORY; MOUSE; NONHUMAN; OBJECT RELATION; PATTERN RECOGNITION; PRIORITY JOURNAL;

ANALYSIS OF VARIANCE; ANILINE COMPOUNDS; ANIMALS; BEHAVIOR, ANIMAL; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; INDANS; INDOLES; MALE; MICE; PIPERIDINES; RECOGNITION (PSYCHOLOGY); SEROTONIN ANTAGONISTS; SEROTONIN RECEPTOR AGONISTS; SULFONAMIDES;

EID: 84858445102     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2012.02.012     Document Type: Article

References (39)

1. Grossberg G.T., Edwards K.R., Zhao Q. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease. J Clin Pharmacol 2006, 46:17S-26S.
2. Chopra K., Misra S., Kuhad A. Current perspectives on pharmacotherapy of Alzheimer's disease. Expert Opin Pharmacother 2011, 12:335-350.
3. Sobow T. Combination treatments in Alzheimer's disease: risks and benefits. Expert Rev Neurother 2010, 10:693-702.
4. Hoyer D., Hannon J.P., Martin G.R. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 2002, 71:533-554.
5. Mowla A., Mosavinasab M., Haghshenas H., Borhani Haghighi A. Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer's dementia? A double-blind, placebo-controlled clinical trial. J Clin Psychopharmacol 2007, 27:484-487.
6. Bockaert J., Claeysen S., Compan V., Dumuis A. 5-HT(4) receptors, a place in the sun: act two. Curr Opin Pharmacol 2011, 11:87-93.
7. Madsen K., Neumann W.J., Holst K., Marner L., Haahr M.T., Lehel S., et al. Cerebral serotonin 4 receptors and amyloid-beta in early Alzheimer's disease. J Alzheimers Dis 2011, 26:457-466.
8. Lezoualc'h F. 5-HT4 receptor and Alzheimer's disease: the amyloid connection. Exp Neurol 2007, 205:325-329.
9. Russo O., Cachard-Chastel M., Riviere C., Giner M., Soulier J.L., Berthouze M., et al. Design, synthesis, and biological evaluation of new 5-HT4 receptor agonists: application as amyloid cascade modulators and potential therapeutic utility in Alzheimer's disease. J Med Chem 2009, 52:2214-2225.
10. Moser P.C., Bergis O.E., Jegham S., Lochead A., Duconseille E., Terranova J.P., et al. SL65.0155, a novel 5-hydroxytryptamine(4) receptor partial agonist with potent cognition-enhancing properties. J Pharmacol Exp Ther 2002, 302:731-741.
11. Lamirault L., Guillou C., Thal C., Simon H. Combined treatment with galanthaminium bromide, a new cholinesterase inhibitor, and RS 67333, a partial agonist of 5-HT4 receptors, enhances place and object recognition in young adult and old rats. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27:185-195.
12. Cachard-Chastel M., Devers S., Sicsic S., Langlois M., Lezoualc'h F., Gardier A.M., et al. Prucalopride and donepezil act synergistically to reverse scopolamine-induced memory deficit in C57Bl/6j mice. Behav Brain Res 2008, 187:455-461.
13. King M.V., Marsden C.A., Fone K.C. A role for the 5-HT(1A), 5-HT4 and 5-HT6 receptors in learning and memory. Trends Pharmacol Sci 2008, 29:482-492.
14. Cavalli A., Bolognesi M.L., Minarini A., Rosini M., Tumiatti V., Recanatini M., et al. Multi-target-directed ligands to combat neurodegenerative diseases. J Med Chem 2008, 51:347-372.
15. Morphy R., Rankovic Z. The physicochemical challenges of designing multiple ligands. J Med Chem 2006, 49:4961-4970.
16. Dere E., Huston J.P., De Souza Silva M.A. The pharmacology, neuroanatomy and neurogenetics of one-trial object recognition in rodents. Neurosci Biobehav Rev 2007, 31:673-704.
17. Sik A., van Nieuwehuyzen P., Prickaerts J., Blokland A. Performance of different mouse strains in an object recognition task. Behav Brain Res 2003, 147:49-54.
18. Sperling R.A., Dickerson B.C., Pihlajamaki M., Vannini P., LaViolette P.S., Vitolo O.V., et al. Functional alterations in memory networks in early Alzheimer's disease. Neuromolecular Med 2010, 12:27-43.
19. Malleret G., Haditsch U., Genoux D., Jones M.W., Bliss T.V., Vanhoose A.M., et al. Inducible and reversible enhancement of learning, memory, and long-term potentiation by genetic inhibition of calcineurin. Cell 2001, 104:675-686.
20. Rolls A., Colas D., Adamantidis A., Carter M., Lanre-Amos T., Heller H.C., et al. Optogenetic disruption of sleep continuity impairs memory consolidation. Proc Natl Acad Sci USA 2011, 108:13305-13310.
21. Kendall I., Slotten H.A., Codony X., Burgueno J., Pauwels P.J., Vela J.M., et al. E-6801, a 5-HT6 receptor agonist, improves recognition memory by combined modulation of cholinergic and glutamatergic neurotransmission in the rat. Psychopharmacology (Berl) 2011, 213:413-430.
22. Furukawa-Hibi Y., Alkam T., Nitta A., Matsuyama A., Mizoguchi H., Suzuki K., et al. Butyrylcholinesterase inhibitors ameliorate cognitive dysfunction induced by amyloid-beta peptide in mice. Behav Brain Res 2011, 225:222-229.
23. Romberg C., Mattson M.P., Mughal M.R., Bussey T.J., Saksida L.M. Impaired attention in the 3xTgAD mouse model of Alzheimer's disease: rescue by donepezil (Aricept). J Neurosci 2011, 31:3500-3507.
24. Lelong V., Dauphin F., Boulouard M. RS 67333 and d-cycloserine accelerate learning acquisition in the rat. Neuropharmacology 2001, 41:517-522.
25. Fontana D.J., Daniels S.E., Wong E.H., Clark R.D., Eglen R.M. The effects of novel, selective 5-hydroxytryptamine (5-HT)4 receptor ligands in rat spatial navigation. Neuropharmacology 1997, 36:689-696.
26. Lelong V., Lhonneur L., Dauphin F., Boulouard M. BIMU 1 and RS 67333, two 5-HT4 receptor agonists, modulate spontaneous alternation deficits induced by scopolamine in the mouse. Naunyn Schmiedebergs Arch Pharmacol 2003, 367:621-628.
27. Hille C., Bate S., Davis J., Gonzalez M.I. 5-HT4 receptor agonism in the five-choice serial reaction time task. Behav Brain Res 2008, 195:180-186.
28. McCarthy A.D., Owens I.J., Bansal A.T., McTighe S.M., Bussey T.J., Saksida L.M. FK962 and donepezil act synergistically to improve cognition in rats: potential as an add-on therapy for Alzheimer's disease. Pharmacol Biochem Behav 2011, 98:76-80.
29. Tsunekawa H., Noda Y., Mouri A., Yoneda F., Nabeshima T. Synergistic effects of selegiline and donepezil on cognitive impairment induced by amyloid beta (25-35). Behav Brain Res 2008, 190:224-232.
30. Lee J.H., Park S.Y., Shin Y.W., Kim C.D., Lee W.S., Hong K.W. Concurrent administration of cilostazol with donepezil effectively improves cognitive dysfunction with increased neuroprotection after chronic cerebral hypoperfusion in rats. Brain Res 2007, 1185:246-255.
31. Eglen R.M., Bonhaus D.W., Johnson L.G., Leung E., Clark R.D. Pharmacological characterization of two novel and potent 5-HT4 receptor agonists, RS 67333 and RS 67506, in vitro and in vivo. Br J Pharmacol 1995, 115:1387-1392.
32. Maurice T., Lockhart B.P. Neuroprotective and anti-amnesic potentials of sigma (sigma) receptor ligands. Prog Neuropsychopharmacol Biol Psychiatry 1997, 21:69-102.
33. Orsetti M., Dellarole A., Ferri S., Ghi P. Acquisition, retention, and recall of memory after injection of RS67333, a 5-HT(4) receptor agonist, into the nucleus basalis magnocellularis of the rat. Learn Mem 2003, 10:420-426.
34. Consolo S., Arnaboldi S., Giorgi S., Russi G., Ladinsky H. 5-HT4 receptor stimulation facilitates acetylcholine release in rat frontal cortex. Neuroreport 1994, 5:1230-1232.
35. Matsumoto M., Togashi H., Mori K., Ueno K., Ohashi S., Kojima T., Yoshioka M. Evidence for involvement of central 5-HT(4) receptors in cholinergic function associated with cognitive processes: behavioral, electrophysiological, and neurochemical studies. J Pharmacol Exp Ther 2001, 296:676-682.
36. Varnäs K., Halldin C., Pike V.W., Hall H. Distribution of 5-HT4 receptors in the postmortem human brain-an autoradiographic study using [125I] SB 207710. Eur Neuropsychopharmacol 2003, 13:228-234.
37. Vilaró M.T., Cortés R., Mengod G. Serotonin 5-HT4 receptors and their mRNAs in rat and guinea pig brain: distribution and effects of neurotoxic lesions. J Comp Neurol 2005, 484:418-439.
38. Bickmeyer U., Heine M., Manzke T., Richter D.W. Differential modulation of I(h) by 5-HT receptors in mouse CA1 hippocampal neurons. Eur J Neurosci 2002, 16:209-218.
39. Feng J., Cai X., Zhao J., Yan Z. Serotonin receptors modulate GABA(A) receptor channels through activation of anchored protein kinase C in prefrontal cortical neurons. J Neurosci 2001, 21:6502-6511.